Skip to main content
OpenTrials
Completed

NCT Number: NCT03523962

Pre-operative Alcohol Skin Solutions in Fractured Extremities

The prevention of infection is an important goal influencing peri-operative care of extremity fracture patients. Standard practice in the operative management of extremity fractures includes sterile technique and pre-operative skin preparation with an antiseptic solution. The available solutions kill bacteria and decrease the quantity of native skin flora, thereby decreasing surgical site infection (SSI). While there is extensive guidance on specific procedures for prophylactic antibiotic use and standards for sterile technique, the evidence regarding the choice of antiseptic skin preparation solution is very limited for extremity fracture surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Royal Columbia Hospital, New Westminster, British Columbia, Canada

Loading trial locations.

About this study

More than one million Americans suffer an extremity fracture (broken bone in the arm, leg, or pelvis) that requires surgery each year. Approximately 5% (or 50,000) of surgical fracture patients develop a surgical site infection (SSI), which is twice the rate among most surgical patients and nearly five times the rate among patients undergoing elective orthopaedic surgeries (e.g. joint replacement). Patients who develop a SSI after their fracture fixation surgery experience a long and difficult treatment pathway. Researchers have identified that when a fracture patient experiences a SSI, they typically undergo at least two additional surgeries to control the infection, spend a median of 14 additional days in the hospital, and have significantly lower health related quality of life (HRQL). Similarly, results from the recently completed Fluid Lavage of Open Wounds (FLOW) trial confirmed that patients who had a SSI, or another complication, that required an additional surgery reported significantly lower physical and mental HRQL in the 12 months following their fracture compared to patients who did not experience a SSI. In the most severe cases, when a SSI cannot be controlled, a limb amputation becomes necessary.

Open fractures, closed lower extremity fractures, and pelvic fractures represent some of the most severe musculoskeletal injuries. Due to their high-energy mechanisms, these fractures are often accompanied by soft-tissue injuries that contribute to unacceptably poor outcomes. The FLOW trial of 2,447 open fracture patients reported a 13.2% incidence of open fracture-related reoperations; Closed fractures of the lower extremity are also at high risk of complications, particularly when compared to closed upper extremity fractures. For example, the rate of SSI in closed tibial plateau and plafond fractures range from 5.6 - 11.9%, although some cohort studies have reported infection rates as high as 25.0%. This is contrast with SSI rates of <5% for common upper extremity fractures like humeral shaft, forearm, or distal radius fractures. This is further illustrated in a series of 214 deep orthopaedic fracture infections, in which 58% occurred in the tibia and ankle, and only 10% occurred anywhere in the upper extremity. Finally, pelvic fractures are associated with some of the most challenging SSIs to treat among closed fractures because of their propensity to gram negative organisms and limitations in reconstruction options post-infection. Ultimately, infectious complications in these fracture populations lead to prolonged morbidity, loss of function, and potential limb loss.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

The open fracture inclusion criteria are:

  • Patients 18 years of age or older.
  • Open fracture of the appendicular skeleton.
  • Received or will receive definitive fracture treatment with a surgical implant(s) (i.e., internal fixation, external fixation, joint prosthesis, etc.).
  • Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.
  • Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
  • Informed consent obtained.
  • Patient enrolled within 3 weeks of their fracture.

The open fracture exclusion criteria are:

  • Fracture of the hand (distal to radial carpal joint).
  • Patients who did not or will not receive the allocated pre-operative surgical preparation solution due to a medical contraindication.
  • Received previous surgical debridement or management of their fracture at a nonparticipating hospital or clinic (as applicable).
  • Open fracture managed outside of the participating orthopaedic service (e.g., foot fracture managed by podiatrist).
  • Chronic or acute infection at or near the fracture site at the time of initial fracture surgery.
  • Burns at the fracture site.
  • Incarceration.
  • Expected injury survival of less than 90 days.
  • Terminal illness with expected survival less than 90 days.
  • Currently enrolled in a study that does not permit co-enrollment.
  • Unable to obtain informed consent due to language barriers.
  • Likely problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  • Prior or current enrollment in a PREP-IT trial.
  • Enrolled in the PREPARE closed cohort.
  • Excluded due to sampling strategy.

The closed fracture inclusion criteria are:

  • Patients 18 years of age or older.
  • Closed fracture of the lower extremity or pelvis.
  • Received or will receive definitive fracture treatment with a surgical implant(s) (i.e., internal fixation, external fixation, joint prosthesis, etc.).
  • Fracture management requires a surgical incision (i.e., for fracture reduction or implant insertion).
  • Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
  • Informed consent obtained.
  • Patient enrolled within 6 weeks of their fracture.

The closed fracture exclusion criteria are:

  • Patients who did not or will not receive the allocated pre-operative surgical preparation solution due to a medical contraindication.
  • Received previous surgical management of their fracture at a non-participating hospital or clinic.
  • Fracture managed outside of the participating orthopaedic service (e.g., foot fracture managed by podiatrist).
  • Chronic or acute infection at or near the fracture site at the time of initial fracture surgery.
  • Burns at the fracture site.
  • Incarceration.
  • Expected injury survival of less than 90 days.
  • Terminal illness with expected survival less than 90 days.
  • Currently enrolled in a study that does not permit co-enrollment.
  • Unable to obtain informed consent due to language barriers.
  • Likely, problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  • Prior or current enrollment in a PREP-IT trial.
  • Enrolled in the PREPARE open cohort.
  • Excluded due to sampling strategy.

Treatment and study plan

DuraPrep

Drug

The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used.

Chloraprep

Drug

The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the product used.

Primary outcomes

  1. Number of Participants With a Superficial Incisional Surgical Site Infection (SSI)

    Time frame: Within 30 days of the patient's last planned fracture management surgery

    Guided by the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network reporting criteria (2017):

    Date of event for infection may occur from the date of fracture to 30 days after the definitive fracture management surgery; AND involves only skin and subcutaneous tissue of the incision; AND patient has at least one of the following:

    • purulent drainage from the superficial incision.
    • organisms identified from an aseptically obtained specimen from the superficial incision or subcutaneous tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment
    • superficial incision that is deliberately opened by a surgeon, and culture or non-culture-based testing is not performed. AND patient has at least one of the following signs or symptoms: pain or tenderness; localized swelling; erythema; or heat.
    • diagnosis of a superficial incisional SSI by the surgeon.
  2. Number of Participants With a Deep Incisional Infection

    Time frame: Within 90 days of the patient's last planned fracture management surgery

    Guided by CDC's National Healthcare Safety Network Surgical Site Infection reporting criteria (2017):

    Deep Incisional Infection:

    Occurs within 90 days post definitive fracture management; & involves fascial/muscle layers; & has at least one of the following:

    • deep incision purulent drainage
    • a deep incision that dehisces, or is opened by a surgeon, and organism is identified by microbiologic testing; or microbiologic testing is not performed & has at least one of the following: fever (> 38 °C); localized pain or tenderness
    • other evidence of deep incision infection on anatomical exam or imaging test

Secondary outcomes

  1. Number of Participants With an Unplanned Fracture-Related Reoperation

    Time frame: Within 12 months of the patient's last planned operation

    Common examples include any unplanned fracture-related surgery that is associated with an infection at the operative site or contiguous to it, a wound-healing problem, or a fracture delayed union or non-union.

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Collaborators

  • McMaster University
  • Patient-Centered Outcomes Research Institute

Registry information

Official study title

PREPARE: A Pragmatic Randomized Trial Evaluating Pre-operative Alcohol Skin Solutions in FRactured Extremites

Acronym: PREPARE

Important dates

Study start
2018
Primary completion
2023
Study completion
2024
First posted
May 14, 2018
Registry last updated
Oct 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.